Nanocell Therapeutics’ Post

We've had the great opportunity to speak to Eric Halioua, CEO of PDC*line Pharma, on the company’s journey from its inception to its current breakthroughs in cancer immunotherapies. Eric shared insights on the drive behind PDC*line Pharma's unique platform, the resilience required to push forward in biotech, and the impact of global partnerships. Stay tuned for more on how PDC*line Pharma is advancing clinical trials and what we can expect to hear from them at Cell and Gene Therapy International Europe, this December! Read more below: #cellandgenetherapy #biotech #bioprocessing

I love the insight to the industry- Proud to be part of a team that brings innovative solutions to these complex challenges, helping our clients deliver better outcomes faster. 💡 #ClinicalTrials #Pharma #Allucent #Innovation #Therapeutics #CellAndGeneTherapy 💡 #ClinicalTrials #Pharma #Allucent #Innovation #Therapeutics #CellAndGeneTherapy

🌟 Join Wren Laboratories for an informative webinar on the integration of #LiquidBiopsy technologies in clinical trials, revolutionizing biomarker discovery and implementation. Discover non-invasive insights into tumor biology and therapeutic responses, as we explore Wren’s innovative approach to #mRNA gene signatures. Dr. Abdel Halim, PharmD, MSc, PhD, DABCC will discuss the clinical applicability of Wren’s novel mRNA gene signatures in enhancing the drug development process, including proof of concept and mechanism studies. ➡️ Learn more + register here: https://buff.ly/4eOkmWE #Biotherapeutics #GeneSignature #Pharmacodynamics #CellAndGeneTherapy #TherapeuticAreas #ProofOfConcept #OncologyDrugs #Oncology #ClinicalResearch #TargetedTherapy #PrecisionMedicine #CancerTreatment #DrugDevelopment

𝑼𝒎𝒐𝒋𝒂 𝑩𝒊𝒐𝒑𝒉𝒂𝒓𝒎𝒂 𝑺𝒆𝒄𝒖𝒓𝒆𝒔 𝑭𝑫𝑨 𝑨𝒑𝒑𝒓𝒐𝒗𝒂𝒍 𝒇𝒐𝒓 𝑮𝒓𝒐𝒖𝒏𝒅𝒃𝒓𝒆𝒂𝒌𝒊𝒏𝒈 𝑰𝒏 𝑽𝒊𝒗𝒐 𝑪𝑨𝑹-𝑻 𝑻𝒉𝒆𝒓𝒂𝒑𝒚 𝑷𝒉𝒂𝒔𝒆 1 𝑻𝒓𝒊𝒂𝒍 🧬💊 Umoja Biopharma has received FDA approval to dose the first patient with a potentially more accessible CAR-T therapy. The company plans to launch a Phase 1 trial this year for UB-VV111, its experimental in vivo gene therapy for blood cancer. Unlike ex vivo CAR-Ts, Umoja's in vivo treatment eliminates the need for the costly and time-consuming process of cell collection, engineering, and delivery. Instead, Umoja’s VivoVec platform helps the body create its own cancer-killing CAR-T cells. Umoja Biopharma is hiring for a Manager, Analytical Development (Louisville, CO Hybrid) https://lnkd.in/erq72GRj #CancerResearch #GeneTherapy #CAR-T #Biotech #FDAApproval #Innovation

Check out the latest issue of Allucent's Monthly Newsletter for biotech industry highlights: https://lnkd.in/gaWYsp9C   Key Highlights in this month's Industry Spotlight: • ADCs, Bispecifics and Radiopharma Take Center Stage at ESMO24 • 3 FDA Approval Dates to Watch in the Year's Final Push • Advancing Precision Oncology: Radionuclide Conjugate and ADC Development Strategies • Gene Therapy Startup Emerges with Green Light for First-of-its-kind Trial • FDA Issues Draft Guidance on Conducting Multiregional Clinical Trials in Oncology • Who's Winning in Biotech's Tight Market?   #Allucent #BringNewTherapiesToLight #ClinicalDevelopment  #Newsletter

We are looking forward to this event! Join Abdel Halim, PharmD, MSc, PhD, DABCC as we discuss how Wren Laboratories approach to mRNA gene signatures is advancing #liquidbiopsy technologies for clinical trials! #biopharma #testing #mRNA #clinicaltrials

Discover the latest insights in Allucent's Monthly Newsletter for the biotech industry: https://lnkd.in/gaWYsp9C This month's Industry Spotlight features: • ADCs, Bispecifics, and Radiopharma leading discussions at ESMO24 • Key FDA approval dates to keep an eye on before year-end • Strategies for advancing precision oncology with radionuclide conjugates and ADCs • A new gene therapy startup gets the green light for a groundbreaking trial • FDA's draft guidance on multiregional clinical trials in oncology • The top contenders in biotech's competitive market

Development of a non-viral #genedelivery platform for #CARTmanufacturing Next week, Stanford Center for Cancer Cell Therapy’s Steven Feldman (Site Head & Scientific Director of the Laboratory for Cell & Gene Medicine) and MaxCyte, Inc.’s James Brady (Senior Vice President, Technical Applications & Customer Support) will explore how non-homologous end joining (NHEJ)-mediated homology-independent targeted insertion (HITI) could be used for efficient CAR gene knock-ins in #Tcells. Attend this webinar to: • Gain a deeper understanding of how to improve CAR-T cell engineering efficiency, scalability, and cell viability • Learn about a non-viral HITI-mediated technique to create CAR gene knock-ins in #Tcells via #nanoplasmid DNA and CRISPR/Cas9 • Explore how a novel HITI-mediated #genedelivery platform can provide enhanced efficiency compared to non-homologous end joining (HDR), based on preclinical studies Register for this upcoming #webinar below:

Next week! Registration still open > Join us as we analyze data emphasizing the significance of employing well-characterized and recallable donors to maintain uniformity in your therapy advancement. In addition, we will cover Xsphera Biosciences' innovative ex vivo efficacy testing platform, which utilizes microfluidics-based technology to provide real-time assessment of CAR-T cell therapy activity and kinetics. During the webinar, Drs. Raluca Dumitru and Aaron Goldman will provide insights on the following topics: - Donor management strategies to improve #celltherapy outcomes · - The impact of source material variability on downstream cell therapy efficiency · - Dynamic ex vivo preclinical efficacy testing models · - The impact of differential gene expression between donors on cell therapy potency Register today: https://okt.to/3Rfp2M #cellsolutions #startingmaterial #celltherapy #webinar #car-t #donormanagement #cellsourcing

Watch a on demand webinar on the development of of non-viral gene delivery platform for CAR-T manufacturing, featuring presentations by @StevenFeldman, Sit Head and Scientific Director of the @Laboratory for Cell & Gene Medicine at Stanford Center for Cancer Cell Therapy, and @James Brady, Senior Vice President, Technical Applications and Customer Support at MaxCyte. Key Highlights Discussed: • Non-viral gene delivery that explores non-viral methods, like HITI, for CAR-T cell manufacturing, which offer a promising alternative to traditional viral methods. • Efficiency and scalability that demonstrates improved cell engineering efficiencies, viabilities, and scalability using nanoplasmid DNA and CRISPR/Cas9. • A comparative analysis, comparing viral and non-viral platforms for GD2 CAR-T manufacturing, showcasing process comparability and feasibility. Watch now on-demand: https://lnkd.in/gdPQsDE8 https://bit.ly/4dTA9CF